Bullous pemphigoid

Signs and symptoms

Clinically, the earliest lesions may appear as a hives-like red raised rash, but could also appear dermatitic, targetoid, lichenoid, nodular, or even without a rash (essential pruritus). Bullous Pemphigoid, is characterized by the subepidermal blisters resulting in tense and less fragile bullae. Tense bullae eventually erupt, most commonly at the inner thighs and upper arms, but the trunk and extremities are frequently both involved. Any part of the skin surface can be involved. Oral lesions are present in a minority of cases. The disease may be acute, but can last from months to years with periods of exacerbation and remission.

Several other skin diseases may have similar symptoms. However, milia are more common with epidermolysis bullosa acquisita, because of the deeper antigenic targets. A more ring-like configuration with a central depression or centrally collapsed bullae may indicate linear IgA disease. Nikolsky's sign is negative, unlike pemphigus vulgaris, where it is positive.

Causes

In most cases of bullous pemphigoid, no clear precipitating factors are identified. Onset of pemphigoid has also been associated with certain drugs, including furosemide, nonsteroidal anti-inflammatory agents, DPP-4 inhibitors, captopril, penicillamine, and antibiotics.

Pathophysiology

The bullae are formed by an immune reaction, initiated by the formation of IgG autoantibodies targeting dystonin, also called bullous pemphigoid antigen 1, and/or type XVII collagen, also called bullous pemphigoid antigen 2, which is a component of hemidesmosomes. A different form of dystonin is associated with neuropathy. Following antibody targeting, a cascade of immunomodulators results in a variable surge of immune cells, including neutrophils, lymphocytes and eosinophils coming to the affected area. Unclear events subsequently result in a separation along the dermoepidermal junction and eventually stretch bullae.

Bullous pemphigoid, goes through two distinct phases: The non-bulbous and the bullous phase.

Non-bulbous phase, involves mild to severe intractable pruritic skin due to the non-specificity of the disease. involving eczematous or urticarial lesions. This phase of Bullous pemphigoid can occur over the time period of weeks to months. In the bullous phase, tense blisters form in an annular shape and are filled with clear fluid. This occurs on the abdomen, limbs and lower trunk. These blisters average between 1cm-4cm in diameter.

Diagnosis

Diagnosis consist of at least 2 positive results out of 3 criteria (2-out-of-3 rule): (1) pruritus and/or predominant cutaneous blisters, (2) linear IgG and/or C3c deposits (in an n- serrated pattern) by direct immunofluorescence microscopy (DIF) on a skin biopsy specimen, and (3) positive epidermal side staining by indirect immunofluorescence microscopy on human salt-split skin (IIF SSS) on a serum sample. Routine H&E staining or ELISA tests do not add value to initial diagnosis.

In the early stages Bullous pemphigoid, particularly in rare forms of the disease, it can be misdiagnosed as the lesions may appear more like prurigo simplex subacuta, chronic prurigo, eczema, urticaria and localized.

Treatment

Treatments include topical steroids such as clobetasol, and halobetasol which in some studies have proven to be equally effective as systemic, or pill, therapy and somewhat safer. Antibiotics such as tetracycline or erythromycin may also control the disease, particularly in patients who cannot use corticosteroids.

The anti-CD20 monoclonal antibody rituximab has been found to be effective in treating some otherwise refractory cases of pemphigoid. A 2010 (updated in 2023) meta-analysis of 14 randomized controlled trials showed that oral steroids and potent topical steroids are effective treatments, although their use may be limited by side-effects, while lower doses of topical steroids are safe and effective for treatment of moderate bullous pemphigoid.

IgA-mediated pemphigoid can often be difficult to treat even with usually effective medications such as rituximab.

Prognosis

Bulbous pemphigoid may be self-resolving in a period ranging from several months to many years even without treatment. Poor general health related to old age is associated with a poorer prognosis.

Epidemiology

Very rarely seen in children, bullous and non-bullous pemphigoid most commonly occurs in people 70 years of age and older. Some sources report it affects men twice as frequently as women, while others report no difference between the sexes.

Many mammals can be affected, including dogs, cats, pigs, and horses, as well as humans. It is very rare in dogs; on average, three cases are diagnosed around the world each year.

Research

Animal models of bullous pemphigoid have been developed using transgenic techniques to produce mice lacking the genes for the two known autoantigens, dystonin and collagen XVII.

References

References

1. (May 2015). "Atypical presentations of bullous pemphigoid: Clinical and immunopathological aspects". Autoimmunity Reviews.
2. Khan Mohammad Beigi, Pooya. (2018). "A clinician's guide to pemphigus vulgaris". Springer.
3. (2019). "Fitzpatrick's Dermatology". McGraw-Hill Education.
4. (2022). "Harrison's Principles of Internal Medicine". McGraw-Hill Education.
5. (2013). "Acantholysis revisited: Back to basics". Indian Journal of Dermatology, Venereology and Leprology.
6. article. 1062391. Bullous Pemphigoid. clinical
7. {{OMIM. 113810. DYSTONIN; DST
8. {{OMIM. 113811. COLLAGEN, TYPE XVII, ALPHA-1; COL17A1
9. (2021-10-04). "Bullous Pemphigoid and Other Pemphigoid Dermatoses". Medicina.
10. (2020-06-29). "Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment". Dermatology Practical & Conceptual.
11. (16 April 2018). "Complement Activation in Inflammatory Skin Diseases". Frontiers in Immunology.
12. (February 2019). "Assessment of Diagnostic Strategy for Early Recognition of Bullous and Nonbullous Variants of Pemphigoid". JAMA Dermatology.
13. (2016-05-21). "Bullous Pemphigoid Challenge: Analysis of Clinical Presentation and Diagnostic Approach". Journal of Dermatology and Clinical Research.
14. (2018). "Effectiveness and Safety of Rituximab in Recalcitrant Pemphigoid Diseases". Frontiers in Immunology.
15. (June 2015). "Persistence of Autoreactive IgA-Secreting B Cells Despite Multiple Immunosuppressive Medications Including Rituximab". JAMA Dermatology.